# Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

> **NCT05041257** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 79 (actual)

## Conditions studied

- Ovarian Cancer
- Peritoneal Cancer
- Fallopian Tube Cancer

## Interventions

- **DRUG:** Mirvetuximab soravtansine

## Key facts

- **NCT ID:** NCT05041257
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-19
- **Primary completion:** 2024-12-12
- **Final completion:** 2024-12-12
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05041257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05041257, "Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05041257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*